News
09-08-2015, 06:02 AM
Oxis Biotech, Inc., a wholly owned subsidiary of Oxis International, Inc., announced today the execution of an exclusive worldwide license agreement to further develop and commercialize DT2219ARL, a novel therapy for the treatment of various human B cell cancers, leukemias and lymphomas.
More... (http://www.news-medical.net/news/20150908/Oxis-Biotech-executes-worldwide-license-agreement-to-develop-commercialize-novel-cancer-therapy.aspx)
More... (http://www.news-medical.net/news/20150908/Oxis-Biotech-executes-worldwide-license-agreement-to-develop-commercialize-novel-cancer-therapy.aspx)